SCHEMBL3154165

SCHEMBL3154165

NCCNC(=O)c1ccc(S(=O)(=O)N(Oc2ccc(Cl)cc2Cl)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
MAOB P27338 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
MCHR1 Q99705 1/20 0.44
CXCR3 P49682 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 1/20 0.43
ACLY P53396 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
GPR27 Q9NS67 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3157034 0.99 KMT2A (0.48) CYP1A2TSHRNFKB1MAOBKMT2A
SCHEMBL3153189 0.90 CA1 (0.46) KMT2AMEN1MCHR1CXCR3SMN1; SMN2
SCHEMBL3153923 0.89 SMN1; SMN2 (0.58) KMT2AMEN1MCHR1CXCR3SMN1; SMN2
SCHEMBL3050363 0.88 CA1 (0.46) TSHRKMT2AMCHR1CXCR3SMN1; SMN2
SCHEMBL3260542 0.86 MCHR1 (0.43) KMT2AMEN1MCHR1CXCR3SMN1; SMN2
SCHEMBL3147735 0.86 MCHR1 (0.42) KMT2AMEN1MCHR1CXCR3SMN1; SMN2
SCHEMBL3137635 0.85 GPR27 (0.47) TSHRKMT2ACXCR3SMN1; SMN2HPGD
SCHEMBL3052659 0.83 TAS2R14 (0.47) KMT2AMEN1CXCR3GPR27MRGPRX4
SCHEMBL15016184 0.83 CHRM1 (0.45) CXCR3
SCHEMBL3148182 0.83 F10 (0.51) SMN1; SMN2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed
EP-2074083-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-01 EP disclosed
WO-2008050168-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 CYP1A2 2734/4885TSHR 1426/4885NFKB1 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.